Lotus Pharmaceutical Co., Ltd.(TW:1795)
NT$156.00-10.50 (-6.31%)
TW:1795
Lotus Pharmaceutical Co., Ltd. financials statements
NT$156.00
At close:-10.50 (-6.31%)
Lotus Pharmaceutical Co., Ltd. (1795) Financial Statements
Lotus Pharmaceutical Co., Ltd. Financial Overview
Lotus Pharmaceutical Co., Ltd.'s market cap is currently NT$44.28B. The company's EPS TTM is NT$14.45; its P/E ratio is 10.79; and it has a dividend yield of 1.64%. Lotus Pharmaceutical Co., Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | NT$ 20.51B | NT$ 18.58B | NT$ 16.96B | NT$ 14.63B | NT$ 12.65B |
| Gross Profit | NT$ 10.64B | NT$ 10.92B | NT$ 9.38B | NT$ 7.81B | NT$ 5.64B |
| Operating Income | NT$ 5.90B | NT$ 6.02B | NT$ 4.90B | NT$ 4.32B | NT$ 2.20B |
| EBITDA | NT$ 7.44B | NT$ 8.21B | NT$ 6.87B | NT$ 5.26B | NT$ 2.93B |
| Net Income | NT$ 4.72B | NT$ 5.07B | NT$ 4.11B | NT$ 3.02B | NT$ 1.40B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | NT$ 7.74B | NT$ 6.03B | NT$ 1.77B | NT$ 1.98B | NT$ 1.61B |
| Total Assets | NT$ 106.15B | NT$ 40.10B | NT$ 32.99B | NT$ 29.53B | NT$ 21.22B |
| Total Debt | NT$ 55.93B | NT$ 13.67B | NT$ 11.58B | NT$ 8.92B | NT$ 6.39B |
| Net Debt | NT$ 48.19B | NT$ 7.64B | NT$ 9.81B | NT$ 6.93B | NT$ 4.78B |
| Total Liabilities | NT$ 82.37B | NT$ 18.92B | NT$ 15.66B | NT$ 15.66B | NT$ 10.15B |
| Stockholders' Equity | NT$ 23.78B | NT$ 21.18B | NT$ 17.33B | NT$ 13.87B | NT$ 11.07B |
| Cash Flow | |||||
| Free Cash Flow | NT$ 3.13B | NT$ 4.69B | NT$ -1.65B | NT$ 650.03M | NT$ -1.50B |
| Operating Cash Flow | NT$ 7.48B | NT$ 6.15B | NT$ 1.61B | NT$ 3.72B | NT$ 119.66M |
| Investing Cash Flow | NT$ -12.47B | NT$ -2.69B | NT$ -3.25B | NT$ -4.66B | NT$ -1.58B |
| Financing Cash Flow | NT$ 6.90B | NT$ 714.09M | NT$ 1.40B | NT$ 1.26B | NT$ 1.66B |
Currency in TWD
